BACILLUS HOSTS FOR PHARMACEUTICAL PROTEIN SECRETION

Information

  • Research Project
  • 3497846
  • ApplicationId
    3497846
  • Core Project Number
    R43GM037880
  • Full Project Number
    1R43GM037880-01
  • Serial Number
    37880
  • FOA Number
  • Sub Project Id
  • Project Start Date
    1/1/1987 - 37 years ago
  • Project End Date
    6/30/1987 - 37 years ago
  • Program Officer Name
  • Budget Start Date
    1/1/1987 - 37 years ago
  • Budget End Date
    6/30/1987 - 37 years ago
  • Fiscal Year
    1987
  • Support Year
    1
  • Suffix
  • Award Notice Date
    -
Organizations

BACILLUS HOSTS FOR PHARMACEUTICAL PROTEIN SECRETION

Bacillus subitilis is an advantageous host organism for the production of foreign proteins at low cost because it has the capacity to secrete proteins into the growth medium at high levels. Several proteins of bacterial origin encoded by plasmid- borne recombinant genes have been secreted by B. subtilis strains at high levels. B. subtilis can secrete several proteins of eukaryotic origin, but results have not been as successful as with proteins of bacterial origin. This proposal is designed to examine the hypothesis that the discrimination against proteins of eukaryotic origin in B. subtilis is related to the timing of proteolytic removal of the N-terminal secretion signal peptide, which occurs later in bacteria than in eukaryotic systems, relative to the synthesis of the protein. Overproduction of the signal peptidase enzyme in B. subtilis is proposed, in order to accelerate signal removal from secreted proteins. To accomplish this, cloning of the B. subtilis gene encoding signal peptidase is proposed. The long-term objective of this proposal is to construct B. subtilis host strains that can secrete proteins of eukaryotic origin at levels comparable to the levels achieved for proteins of bacterial origin. Such strains would make possible the production at low cost of proteins of pharmaceutical interest, some of which cannot be produced in active form in currently available microbial systems.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    GENEX CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    GAITHERSBURG
  • Organization State
    MD
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    20877
  • Organization District
    UNITED STATES